Koh Ji Qs, Walton Antony, Marasco Silvana, Duffy Stephen J
Department of Cardiology, Alfred Hospital, Melbourne, Victoria, Australia.
Department of Cardiothoracic Surgery, Alfred Hospital, Melbourne, Victoria, Australia.
Future Cardiol. 2019 Jul;15(4):281-293. doi: 10.2217/fca-2018-0082. Epub 2019 May 10.
Mitral regurgitation is the most prevalent yet undertreated valvulopathy despite its adverse prognosis. With the emergence of transcatheter mitral interventions, the potential for this huge unmet disease burden to be addressed may finally be realized. Medtronic Intrepid™ Transcatheter Mitral Valve Replacement System represents one of several novel solutions. Based on early data from the pilot study, its efficacy and clinical utility is currently being tested against the mainstay treatment of surgical mitral valve replacement in a randomized trial. While there remain significant challenges before transcatheter mitral intervention can become part of the routine treatment algorithm, the authors are optimistic that transcatheter mitral valve repair and intervention have the potential in revolutionizing the management of severe symptomatic mitral regurgitation.
二尖瓣反流是最常见但治疗不足的瓣膜病,尽管其预后不良。随着经导管二尖瓣介入治疗的出现,解决这一巨大未满足疾病负担的潜力最终可能得以实现。美敦力Intrepid™经导管二尖瓣置换系统是几种新解决方案之一。根据初步研究的早期数据,目前正在一项随机试验中,将其疗效和临床实用性与外科二尖瓣置换的主要治疗方法进行对比测试。虽然在经导管二尖瓣介入治疗成为常规治疗方案的一部分之前仍存在重大挑战,但作者乐观地认为,经导管二尖瓣修复和介入治疗有可能彻底改变严重症状性二尖瓣反流的治疗方式。